# psoriasis - gpt-5.6-luna

- Benchmark system: raw
- Repeat: 7
- Task type: DISEASE-STATE
- Tissue / sample source: lesional skin
- Comparison or endpoint: psoriatic lesional skin versus normal control skin
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: disabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: OpenAI / gpt-5.6-luna
- Message SHA-256: d1a33d3f606c81814c4fb94a6c63c8f1abebd3bde37d769e82eae4772d8ff873
- Response HTTP status: 200
- Prompt tokens: 3907
- Completion tokens: 5227
- Reasoning tokens: 
- Total tokens: 9134
- API requests reported: 
- Elapsed seconds: 97.592
- Final benchmark system: raw; file rank 5/5; original repeat 7; model vendor: OpenAI

---
## 1. Overall biological interpretation

The transcriptomic profile is strongly consistent with an activated psoriatic lesion rather than normal skin. The dominant signal is a coordinated epidermal–immune inflammatory state characterized by:

- Very strong induction of the **IL-36/IL-20 inflammatory axis**.
- Marked activation of **antimicrobial and neutrophil-associated programs**.
- Extensive **keratinocyte hyperplasia, stress, and altered terminal differentiation/barrier biology**.
- Increased expression of chemokine and immune-modulatory genes, including **CXCL13, CXCR2, CD274, GPR15LG, and PRKCQ**.
- Additional changes in lipid mediator, tryptophan, and epithelial metabolic pathways, although these are less securely interpretable from the supplied gene list alone.

The largest effects include **IL36A, DEFB4A/B, PI3, S100A7A, S100A12, SERPINB4, SPRR-family genes, and IL19**, with FDR values far below \(10^{-70}\). These are unlikely to represent isolated single-gene abnormalities; together they indicate a lesion-level inflammatory and epidermal remodeling program. However, bulk lesional skin cannot distinguish altered transcription within resident cells from changes in cellular composition, particularly increased keratinocytes, neutrophils, and other immune cells.

No formal pathway enrichment results, sample sizes, covariate information, or independent replication data were provided. Therefore, pathway assignments below are biologically informed interpretations of the gene set rather than results of a performed enrichment analysis.

---

## 2. Core biological programs

### Program 1: IL-36–IL-20 inflammatory cytokine network

**Direction:** Upregulated in lesional skin.

**Major supporting genes:**

- **IL36A**, log2FC 11.37, FDR \(1.65\times10^{-98}\)
- **IL36G**, log2FC 5.68, FDR \(1.43\times10^{-90}\)
- **IL19**, log2FC 7.58, FDR \(9.04\times10^{-84}\)
- **IL20**, log2FC 5.67, FDR \(2.85\times10^{-71}\)
- **IL26**, log2FC 4.36, FDR \(3.79\times10^{-65}\)
- **IL36RN**, log2FC 3.01, FDR \(3.85\times10^{-62}\)
- **IRAK2**, **TNIP3**, and **ZC3H12A**, all upregulated

**Most appropriate pathway terminology:**

- Reactome: **Interleukin-1 family signaling** and inflammatory cytokine signaling
- GO: **cytokine-mediated signaling pathway**, **inflammatory response**
- Disease-relevant pathway concept: **IL-36/IL-20 receptor signaling**

**Interpretation:**

The simultaneous induction of multiple IL-36 and IL-20-family ligands is stronger evidence than the elevation of any one cytokine. IL-36 cytokines are predominantly associated with epithelial/keratinocyte inflammatory activation, whereas IL-19 and IL-20 participate in keratinocyte–immune feedback. Increased **IL36RN**, which encodes an IL-36 receptor antagonist, suggests an endogenous counter-regulatory response rather than absence of pathway activation. The presence of **IRAK2**, **TNIP3**, and **ZC3H12A** is compatible with activation and attempted regulation of innate inflammatory signaling.

**Evidence strength:** **Strongly supported hypothesis.**

- **Direct dataset evidence:** multiple pathway-related genes show very large positive fold changes and extremely low FDRs.
- **Pathway evidence:** these genes are members of related cytokine and innate inflammatory signaling systems.
- **Disease-association evidence:** IL-36 and IL-20-family signaling has substantial prior relevance to psoriasis and psoriatic inflammation.
- **Limitation:** transcript abundance does not establish cytokine protein secretion, receptor activation, or causal necessity. IL36RN induction may reflect feedback rather than effective pathway inhibition.

---

### Program 2: Antimicrobial, neutrophil-associated, and innate barrier defense

**Direction:** Upregulated.

**Major supporting genes:**

- **DEFB4A**, log2FC 11.18
- **DEFB4B**, log2FC 11.03
- **DEFB103A/B**, log2FC approximately 5.76
- **S100A8**, log2FC 7.73
- **S100A12**, log2FC 8.33
- **PI3**, log2FC 9.24
- **TCN1**, log2FC 8.04
- **PLBD1**, **CXCR2**, **GPR15LG**, and **HPSE**, all upregulated

**Most appropriate pathway terminology:**

- GO: **antimicrobial humoral response**, **defense response to bacterium**, **neutrophil chemotaxis**
- Reactome: **antimicrobial peptides**, **innate immune system**
- Hallmark: **Inflammatory Response**

**Interpretation:**

The coordinated elevation of beta-defensins, protease inhibitors, S100A8/S100A12, PI3, and neutrophil-associated genes indicates a highly activated antimicrobial and innate inflammatory environment. This program is biologically compatible with the characteristic inflammatory milieu of psoriatic plaques, where keratinocytes produce antimicrobial peptides and chemotactic factors and where myeloid-cell recruitment can be enhanced.

**Evidence strength:** **Strong for the existence of an innate defense signature; moderate for increased neutrophil abundance.**

- **Direct dataset evidence:** numerous independent antimicrobial and myeloid-associated genes are strongly upregulated.
- **Pathway evidence:** the genes span antimicrobial peptide production, alarmin biology, and neutrophil recruitment.
- **Tissue evidence:** these genes are compatible with lesional epidermis and inflammatory infiltrates.
- **Major limitation:** bulk tissue cannot determine whether the signal reflects keratinocyte activation, increased neutrophil/myeloid content, or both. **TCN1, PLBD1, and S100A12** may be particularly sensitive to cellular composition.

---

### Program 3: Epidermal hyperplasia, keratinocyte stress, and altered differentiation/barrier formation

**Direction:** Upregulated.

**Major supporting genes:**

- **KRT6A**, log2FC 4.30
- **GJB2** and **GJB6**, log2FC 4.42 and 3.02
- **SPRR2A/B/D/E/F/G**, **SPRR3**
- **LCE3A** and **LCE3D**
- **SERPINB3**, **SERPINB4**, **SERPINB11**, and **SERPINB13**
- **S100A7**, **S100A7A**
- **FABP5**, **TMPRSS11D**, **KLK13**, and **PRSS27**
- **RRM2** and **CCNE1**, consistent with increased proliferative activity

**Most appropriate pathway terminology:**

- GO: **epidermis development**, **keratinocyte differentiation**, **skin barrier development**
- Reactome: **formation of the cornified envelope**
- Hallmark: **Epithelial–Mesenchymal Transition** is not a precise match and should not be used as the primary label; **E2F targets** or **G2M checkpoint** would require broader proliferation evidence than is available here.

**Interpretation:**

The large coordinated increase in small proline-rich proteins, late cornified envelope genes, keratins, connexins, S100A7-family genes, and serine protease-associated genes is characteristic of epidermal remodeling. **KRT6A**, **RRM2**, and **CCNE1** support a hyperproliferative or activated keratinocyte state, while SPRR/LCE/SERPINB genes indicate altered differentiation and barrier-associated programs. This is more consistent with an activated, thickened, stressed epidermis than with simple generalized inflammation.

**Evidence strength:** **Strongly supported at the tissue-transcriptional level.**

- **Direct dataset evidence:** many structurally and functionally related epidermal genes are coordinately upregulated.
- **Ontology/pathway evidence:** these genes map naturally to cornified envelope, epidermal differentiation, and cell-cycle-related programs.
- **Disease evidence:** epidermal hyperplasia and abnormal differentiation are established features of psoriasis.
- **Limitation:** bulk RNA-seq cannot distinguish true per-cell induction from a greater proportion of epidermal cells in the lesional sample. Increased epidermal thickness alone can amplify these transcripts.

---

### Program 4: Inflammatory leukocyte recruitment and immune modulation

**Direction:** Upregulated.

**Major supporting genes:**

- **CXCL13**, log2FC 5.89
- **CXCR2**, log2FC 2.70
- **GPR15LG**, log2FC 5.52
- **CD274**, log2FC 3.44
- **PRKCQ**, log2FC 2.88
- **ADAP2**, **TRIM15**, **IRAK2**, and **WNT5A**
- **S100A8/S100A12**, which also contribute to myeloid inflammatory recruitment

**Most appropriate pathway terminology:**

- GO: **leukocyte chemotaxis**, **cellular response to cytokine**, **positive regulation of immune response**
- Reactome: **chemokine receptors bind chemokines** and **immune system**
- Caution: the supplied genes do not establish a complete or specific T-cell, B-cell, or neutrophil pathway.

**Interpretation:**

The profile supports increased immune-cell recruitment and immune-regulatory activity within the lesion. **CXCL13** suggests a chemokine-rich local environment, while **CXCR2** is compatible with neutrophil-oriented chemotactic signaling. **CD274/PD-L1** indicates local immune checkpoint or inflammatory adaptation. **PRKCQ** may reflect T-cell-associated signaling, but its elevation alone does not prove increased T-cell abundance or activation.

**Evidence strength:** **Moderate.**

- **Direct dataset evidence:** multiple chemokine, receptor, immune-adaptor, and checkpoint genes are upregulated.
- **Disease evidence:** leukocyte infiltration and cytokine-driven recruitment are established in psoriasis.
- **Limitation:** the precise leukocyte populations and functional consequences cannot be inferred from this list. CXCL13 is not specific to one immune cell type or disease mechanism, and its elevation could reflect local inflammation rather than organized lymphoid structures.

---

### Program 5: Lipid mediator, tryptophan, and epithelial metabolic remodeling

**Direction:** Predominantly upregulated, with selected downregulated metabolic genes.

**Major supporting genes:**

- **PLA2G4D**, log2FC 4.61
- **PLA2G4E**, log2FC 2.47
- **KYNU**, log2FC 4.42
- **FABP5**, log2FC 3.64
- **AKR1B10**, log2FC 6.27
- **AKR1B15**, log2FC 5.23
- **ABCG4**, log2FC 4.75
- **CYP2W1**, log2FC −4.70
- **UGT3A2**, log2FC −4.59

**Most appropriate pathway terminology:**

- GO: **arachidonic acid metabolic process**, **lipid metabolic process**, **tryptophan catabolic process**
- Reactome: **metabolism of lipids** and **tryptophan catabolism**
- KEGG: **arachidonic acid metabolism** and **tryptophan metabolism**, subject to confirmation by formal enrichment

**Interpretation:**

The combined elevation of phospholipase-related genes, FABP5, KYNU, and reductase genes suggests remodeling of lipid mediator handling and inflammatory metabolism in lesional skin. **PLA2G4D** is particularly compatible with altered epidermal lipid mediator production. However, the downregulated genes do not form a sufficiently coherent independent program from the supplied table, and some loci may be tissue- or cell-type-dependent.

**Evidence strength:** **Exploratory.**

- **Direct dataset evidence:** several related metabolic genes are altered, with both positive and negative directions.
- **Pathway evidence:** gene functions suggest lipid and tryptophan metabolism.
- **Limitation:** no metabolomic or lipid mediator measurements are available, and transcript changes do not establish altered enzymatic flux. This program should not be prioritized above the cytokine, antimicrobial, or epidermal programs without pathway-level enrichment and biochemical validation.

---

## 3. Key genes and interaction modules

The following candidates are prioritized as modules or representative genes rather than as isolated disease drivers.

| Candidate | Dataset direction | Potential role | Nature of proposed relationship | Evidence and caution |
|---|---:|---|---|---|
| **IL36A–IL36G–IL36RN module** | All upregulated; IL36A has log2FC 11.37 | Central epithelial inflammatory signaling with compensatory antagonism | **Pathway co-membership** and **regulatory feedback**; receptor-mediated signaling is biologically plausible, but direct protein interaction among these genes is not implied | Strong dataset and disease-association support; protein activity and receptor activation remain unmeasured |
| **IL19–IL20–IL26 module** | Upregulated | Cytokine-mediated keratinocyte–immune amplification | **Pathway co-membership** and likely **indirect paracrine relationships** | Multiple genes support a cytokine network; the dataset cannot establish ligand source, target cells, or causality |
| **DEFB4A/B–DEFB103A/B module** | Strongly upregulated | Antimicrobial defense and inflammatory epithelial signaling | **Co-expression/pathway co-membership**, not direct physical interaction | Very strong dataset support; may reflect both keratinocyte activation and increased epidermal representation |
| **S100A8–S100A12 module** | Strongly upregulated | Myeloid/neutrophil-associated inflammation and alarmin activity | Known functional cooperation is possible, but this dataset demonstrates only **co-expression**; direct physical interaction should not be inferred here | Strong inflammatory signal; highly vulnerable to myeloid-cell composition |
| **CXCL13–CXCR2 chemotactic module** | Both upregulated | Immune-cell recruitment | **Indirect/putative relationship**; CXCR2 is not established here as a receptor for CXCL13, so they should not be treated as a ligand–receptor pair | Both are elevated, but their co-occurrence does not demonstrate a direct signaling axis |
| **SPRR/LCE–SERPINB–KRT6A epidermal module** | Broadly upregulated | Cornified envelope, keratinocyte stress, altered differentiation, and hyperplasia | **Pathway co-membership** and **co-expression** | Strong tissue-level support; per-cell regulation versus epidermal expansion is unresolved |
| **S100A7/S100A7A–PI3 antimicrobial epithelial module** | Upregulated | Inflammatory epidermal defense and protease regulation | **Pathway co-membership** and likely **indirect functional relationship** | Strong independent gene-level support; no direct physical interaction is established from the table |
| **PLA2G4D/E–FABP5 lipid mediator module** | Upregulated | Epidermal lipid handling and inflammatory lipid signaling | **Metabolic pathway co-membership**; enzyme–substrate relationships are putative, not demonstrated | Biologically plausible but requires lipidomic or enzymatic validation |
| **CD274–inflammatory cytokine module** | CD274 upregulated | Local immune-modulatory adaptation | **Regulatory/indirect relationship** with inflammatory signaling; not a demonstrated direct interaction with IL-36 or IL-20 | Strong expression signal, but functional PD-L1 activity and immune consequences are unknown |
| **RRM2–CCNE1 proliferative module** | Both upregulated | Increased cell-cycle activity in lesional epidermis | **Pathway co-membership**, potentially co-regulated | Consistent with hyperproliferation, but a larger cell-cycle signature and histologic confirmation are needed |

No direct physical protein–protein interaction can be concluded from the supplied differential-expression table. Statements above involving interaction are therefore restricted to regulatory, co-expression, pathway, or indirect relationships.

---

## 4. Validation priorities

### 1. IL-36/IL-20 signaling as a lesion-amplifying mechanism  
**Classification:** Mechanistic hypothesis  
**Status:** Supported hypothesis

**Why prioritize:** IL36A, IL36G, IL19, and IL20 are among the most strongly induced genes, and IL36RN is also elevated, suggesting active signaling with feedback regulation.

**Current evidence:** Large effect sizes across several pathway members, not merely one disease-associated gene.

**External evidence:** Prior psoriasis studies support IL-36-family involvement in keratinocyte inflammation and psoriasiform disease. However, transcriptomic evidence alone does not prove that this axis initiates or sustains the lesion in these samples.

**Next step:** Measure IL-36 and IL-20-family proteins, receptor expression, phospho-signaling, and downstream transcriptional activity in lesional versus control skin. Use primary keratinocyte organoids or ex vivo skin with pathway blockade and rescue experiments.

**Interpretive level:** Supported hypothesis, not established causality.

---

### 2. Antimicrobial/neutrophil signature: activation versus cellular composition  
**Classification:** Confounding or composition check  
**Status:** Established evidence for a tissue signature; exploratory regarding its cellular source

**Why prioritize:** DEFB4A/B, S100A8/A12, PI3, TCN1, PLBD1, and CXCR2 are extremely strongly altered, but several can be driven by changes in cell abundance.

**Current evidence:** Robust bulk-tissue signal across epithelial and myeloid-associated genes.

**External evidence:** Psoriatic lesions commonly contain activated keratinocytes and inflammatory myeloid/neutrophil populations. These external facts support the interpretation but do not resolve composition.

**Next step:** Perform single-cell or spatial transcriptomics, histology, and immunostaining for keratinocytes, neutrophils, monocytes, and other leukocyte populations. Apply cell-type deconvolution using validated reference signatures.

**Interpretive level:** Established as a bulk-lesion signature; cell-specific attribution remains exploratory.

---

### 3. Epidermal differentiation and hyperplasia module  
**Classification:** Biomarker  
**Status:** Established tissue-level association

**Why prioritize:** The SPRR, LCE, SERPINB, KRT6A, S100A7, GJB2/GJB6, RRM2, and CCNE1 changes form a broad and coherent epidermal response.

**Current evidence:** Numerous genes across differentiation, barrier, stress, and proliferation are concordantly upregulated.

**External evidence:** Epidermal thickening, altered differentiation, and barrier disruption are well-established histopathologic features of psoriasis.

**Next step:** Correlate module scores with lesion thickness, Ki-67 staining, transepidermal water loss, and clinical severity. Validate protein expression by immunohistochemistry or targeted proteomics.

**Interpretive level:** Established for association with lesional epidermal remodeling; not evidence that any individual gene is a causal therapeutic target.

---

### 4. PLA2G4D/E–FABP5 inflammatory lipid remodeling  
**Classification:** Mechanistic hypothesis  
**Status:** Exploratory hypothesis

**Why prioritize:** PLA2G4D/E, FABP5, and several metabolic genes suggest altered epidermal lipid mediator biology, which could connect barrier dysfunction to inflammation.

**Current evidence:** Concordant upregulation of several genes, but the overall program is weaker and less internally complete than the cytokine or epidermal modules.

**External evidence:** Epidermal lipid metabolism is relevant to barrier function and inflammation, but the supplied data do not establish a specific lipid mediator or enzymatic flux.

**Next step:** Perform targeted lipidomics, measure phospholipase activity and eicosanoid-related metabolites, and perturb PLA2G4D/E or FABP5 in keratinocytes and organotypic skin.

**Interpretive level:** Exploratory hypothesis.

---

### 5. CXCL13-associated immune organization and CD274 expression  
**Classification:** Interaction / network hypothesis  
**Status:** Exploratory hypothesis

**Why prioritize:** CXCL13 and CD274 are strongly elevated, and the broader dataset contains evidence of immune recruitment and local immune modulation.

**Current evidence:** Increased CXCL13, CD274, CXCR2, GPR15LG, PRKCQ, and inflammatory genes.

**External evidence:** CXCL13 can be associated with inflammatory immune organization, while PD-L1 is commonly induced by inflammatory cytokines. Nevertheless, their presence does not prove tertiary lymphoid structure formation, a specific lymphocyte composition, or a therapeutically actionable checkpoint dependency.

**Next step:** Use spatial transcriptomics and multiplex immunofluorescence to identify CXCL13-producing cells, PD-L1-expressing cells, B/T-cell organization, and proximity relationships. Test cytokine-induced CD274 expression in relevant cell types.

**Interpretive level:** Exploratory network hypothesis.

---

## 5. Limitations and alternative explanations

1. **Cellular composition and tissue architecture**  
   Lesional skin likely differs from normal skin in epidermal thickness and immune-cell abundance. This can inflate keratinocyte, neutrophil, and antimicrobial transcripts without implying equivalent per-cell regulation. Single-cell, spatial, histologic, and deconvolution analyses are needed.

2. **Association versus causation**  
   Extremely low FDR values establish statistical differences, not causal mechanisms. For example, IL36A may be a driver, amplifier, or consequence of inflammation. Perturbation experiments are required.

3. **Clinical heterogeneity and treatment exposure**  
   Disease duration, plaque severity, recent topical or systemic therapy, body site, and lesion chronicity can substantially alter cytokine and epidermal signatures. These covariates were not supplied.

4. **Broad or overlapping pathway interpretation**  
   Many genes participate in multiple inflammatory or epithelial processes. Formal enrichment using the complete tested gene universe, effect-size-aware methods, and independent replication would reduce overinterpretation. Several downregulated genes, including **BTC, CYP2W1, UGT3A2, and selected long noncoding transcripts**, do not define a confident coherent program from this table alone.

5. **Technical and annotation limitations**  
   The list includes pseudogenes, long noncoding RNAs, and uncharacterized loci. Their biological interpretation may be uncertain, and platform, batch, normalization, and sample-size information are unavailable. The magnitude of some fold changes should therefore be confirmed by independent assays.

## Bottom line

The most defensible interpretation is a coordinated **IL-36/IL-20-driven inflammatory epidermal state with strong antimicrobial defense, myeloid-associated inflammation, and keratinocyte hyperplasia/differentiation remodeling**. These conclusions are supported by multiple highly significant genes and established psoriasis biology. The main unresolved issue is whether the observed signal reflects altered regulation within specific cells, altered cellular composition, or both. The highest-value next experiments are therefore spatial or single-cell localization, protein-level cytokine validation, and functional perturbation of the IL-36/IL-20 axis rather than assigning causality to individual differentially expressed genes.
